Pharma Medical News about Erlotinib

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kuehn BM - The US Food and Drug Administration is alerting physicians to new safety warnings on the label of erlotinib, a drug approved for the treatment of certain patients with lung or pancreatic cancer, that warn of reports of serious gastrointestinal tract, skin, and ocular disorders in patients taking the drug.

<< Previous
FDA Tells Drug and Device Makers to Give Balanced Picture of...

Next >>
New Developments for "CHUGAI ONCOLOGY": Establishment of "Cancer...

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
Lung Cancer, 10/07/09 Relevance Score: 87%

Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Cancer Science, 11/16/09 Relevance Score: 85%

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09 Relevance Score: 85%

Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Journal of Clinical Oncology, 11/12/09 Relevance Score: 83%

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09 Relevance Score: 80%